Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy, to strengthen its clinical-stage pipeline, according to a press release.“Glaucoma treatment has always been focused on loweri…
Author: Healio ophthalmology
K8 inhibitor yields positive efficacy, safety in GA at 3 months in small trial
The K8 implant, a first-in-class dual inflammasome inhibitor, demonstrated positive efficacy and safety at 3 months in five patients with bilateral geographic atrophy, according to a press release from Inflammasome Therapeutics.In the clinical trial, e…
Stand-alone Omni surgery reduces IOP, medication use at 36 months
Stand-alone canaloplasty and trabeculotomy with the Omni surgical system showed positive real-world outcomes in reducing IOP and medication use, according to a study published in American Journal of Ophthalmology.“This study is both significant and uni…
Linsitinib for thyroid eye disease shows proptosis reduction, safety in phase 2b/3 trial
Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release from Sling Therapeutics.“In this trial, patients demon…
Bausch + Lomb launches enVista Aspire IOLs in Europe
Bausch + Lomb launched the enVista Aspire monofocal and toric IOLs in the European Union, according to a press release.Using intermediate optimized optics, the lenses offer a range of vision beyond one focal point. Additionally, the toric lens can trea…
VIDEO: ‘Still in the dark ages’ in how to best monitor geographic atrophy
CHICAGO — In this video, Clement K. Chan, MD, FACS, discusses highlights from the AAO meeting, including presentations on pegcetacoplan and avacincaptad pegol for the treatment of geographic atrophy.In addition, Chan, a retina specialist at Desert Reti…
Study evaluates visual function, OCTA in eyes with PDR, macular capillary nonperfusion
The foveal avascular zone, or FAZ, area deteriorated at 12 months in eyes with stable laser-treated proliferative diabetic retinopathy and macular capillary nonperfusion, but vision loss was not common, according to a study.“With the advent of optical …
Character Biosciences, Bausch + Lomb to collaborate on development of AMD treatments
Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments for age-related macular degeneration, according to a press release.The collaboration will combine Character Bio’s AI-powered an…
Q&A: Pantheon Vision developing alternative to donor tissue for corneal transplants
Despite a worldwide need for more corneal transplant tissue, few options exist beyond human donors.According to a study published in JAMA Ophthalmology, just one cornea was available for every 70 needed in 2012.John W. Sheets, PhD, president and CEO of…
VIDEO: Multimodal imaging may make GA monitoring more precise
CHICAGO — In this video, Clement K. Chan, MD, FACS, discusses a presentation from the AAO meeting on multimodal imaging to assess geographic atrophy.In a session on diagnostic techniques for identifying and monitoring atrophy in age-related macular deg…
VIDEO: AREDS vitamins may slow GA; C1q inhibitor shows visual acuity signal
CHICAGO — In this video from the AAO meeting, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses the role of AREDS vitamins in slowing the progression of geographic atrophy.“That is something we hadn’t really thought was a benefi…
RhyGaze raises $86 million to develop vision restoration gene therapy
RhyGaze secured $86 million in a Series A financing round, which will be used to further the development of the company’s lead candidate gene therapy for optogenetic vision restoration, according to a press release.GV led the financing round. Contribut…
FDA approves Zeiss Mel 90 excimer laser
The FDA approved the Zeiss Mel 90 excimer laser for the treatment of myopia, hyperopia and mixed astigmatism, according to a press release.The Mel 90 integrates into the Zeiss Corneal Refractive Workflow and complements the Zeiss VisuMax 800 with SMILE…
4D-150 for DME moving to phase 3 trial following positive interim data
4D Molecular Therapeutics reported positive interim data from the first part of the SPECTRA clinical trial investigating 4D-150 in patients with diabetic macular edema, according to a press release.“In the past, intravitreal approaches for sustained de…
City Therapeutics, Bausch + Lomb enter strategic collaboration for GA treatment
City Therapeutics and Bausch + Lomb have entered into a strategic collaboration focused on the development of an RNA interference-based treatment for geographic atrophy, according to a press release.City will use its RNA interference (RNAi) engineering…
VIDEO: Home OCT offers precise retinal treatment personalization with AI
NEW YORK — In this presentation from OSN New York Retina, Majda Hadziahmetovic, MD, of Duke University, discusses the growing role of Home OCT and how it offers precise personalization in retinal disease treatment.According to Hadziahmetovic, AI is use…
VIDEO: Home OCT offers precise retinal treatment personalization with AI
NEW YORK — In this presentation from OSN New York Retina, Majda Hadziahmetovic, MD, of Duke University, discusses the growing role of Home OCT and how it offers precise personalization in retinal disease treatment.According to Hadziahmetovic, AI is use…
VIDEO: Expert shares thoughts on gel stent implantation
NEW YORK — In this presentation from OSN New York, Thomas W. Samuelson, MD, of Minnesota Eye Consultants, uses surgical footage to demonstrate implantation of the Xen gel stent for the treatment of glaucoma.Samuelson discussed why the Xen (Allergan/Abb…
Brimochol PF achieves endpoints in second phase 3 presbyopia trial
Patients with presbyopia experienced improvements in near vision after treatment with Brimochol PF in a second phase 3 pivotal trial, according to a press release from Tenpoint Therapeutics.
The BRIO-II trial met prespecified primary endpoints agreed to by the FDA, European Medicines Agency and UK Medicines and Healthcare products Regulatory Agency. Brimochol PF (carbachol/brimonidine tartrate fixed-dose combination) demonstrated improvements in near vision vs. vehicle at all study time points up to 8 hours (P
Part B of phase 1/2 X-linked retinoschisis gene therapy trial initiated
Atsena Therapeutics initiated part B of the phase 1/2 LIGHTHOUSE study investigating ATSN-201 for the treatment of X-linked retinoschisis, according to a press release.The multicenter clinical trial will include nine adult patients and three pediatric …